Korean Derma Cosmetics Brands Building Momentum at Olive Young Heading Into 2026

AESTURA's ATOBARRIER365 Cream has won Olive Young's cream category five years running, 2021 through 2025, the longest active streak among Korean dermocosmetic lines sold through the retailer. Olive Young's 2025 Awards graded roughly 180 million purchase transactions across 40 categories and 166 products, and independent brand lines took about 75% of the wins, a share that includes Torriden's triple crown across serum, mask pack and lip care, and Anua's multiple category wins built on its heartleaf toner. d'Alba's overseas sales grew about 210% year over year in 2024, while Medicube's parent APR Corp reported nine-month 2025 revenue of $666 million, up 100% year over year, following a February 2024 KOSPI listing. Dr.G, folded into L'Oreal Groupe in December 2024, and the pharmaceutical-affiliate lines ZEROID and Easydew round out a shelf where legacy dermatology names and venture-backed independents now sit on the same award tables.

AESTURA ATOBARRIER365 Cream

AESTURA's ATOBARRIER365 Cream carries an 80ml format and a listed price near ₩33,000 on Olive Young Korea's product page, checked against the retailer's own promotion tag reading '올영 어워즈 1등 크림.' The formula targets skin-barrier repair for sensitive and atopic-prone skin, developed with input the brand credits to roughly 60 dermatologist advisors and a physician research group that meets quarterly, according to Amorepacific's corporate site. AESTURA is a wholly owned Amorepacific line, and the cream's win in the Olive Young Awards cream category has run five consecutive years, 2021 through 2025, ranking first in 2024 per AESTURA's own award announcement. No certification record, such as a COSMOS or MFDS functional-cosmetic filing, surfaced for this specific SKU during this review, though that gap does not affect the award history above. The product is cross-listed on Olive Young Korea, Olive Young Global and Olive Young's US storefront, giving it wider retail reach than most of the other lines profiled here.

Dr.G Red Blemish Clear Soothing Cream

A 70ml tube of Dr.G's Red Blemish Clear Soothing Cream has sold across a discounted range of roughly ₩24,600 to ₩38,000 on Olive Young Korea, depending on the promotion cycle active when checked in 2025. The formula centers on centella asiatica extract, madecassoside and niacinamide for redness and blemish-prone skin, and Dr.G markets it as a bestseller of about ten years standing. Gowoonsesang Cosmetics, Dr.G's parent, was acquired by L'Oreal Groupe under an agreement announced in December 2024, moving the once-independent dermatologist-founded brand under a global ownership structure. Olive Young's own listing references seven consecutive years of award recognition for the line, though a single confirmed current price across every SKU in the family could not be pinned down from the pages reviewed. There are in fact two current versions sold side by side, the original Soothing Cream and a renewed EX formula built around a '10-Cica Exosome' claim.

Torriden DIVE-IN Low Molecule Hyaluronic Acid Serum

Torriden prices the DIVE-IN Low Molecule Hyaluronic Acid Serum at ₩16,900 for a 50ml bottle on its own site, torriden.com, the clearest single-unit figure found across any brand in this comparison. The serum builds on a multi-molecular-weight hyaluronic acid system the brand calls '5D,' aimed at both surface and deep hydration rather than a specific skin condition. It anchored Torriden's triple crown at the 2025 Olive Young Awards, taking wins in the serum, mask pack and lip care categories, and the brand maintains an active dedicated page on Olive Young Global. Domestic Olive Young listings run mostly as bundles rather than a plain single unit, spanning roughly ₩25,500 for a pad-inclusive set to about ₩38,000 for a sun cream double pack, so shoppers comparing the standalone price should check the official site figure above rather than a bundle total.

Medicube Zero Pore Pad 2.0

Medicube's Zero Pore Pad 2.0 sits inside the brand's pore-care toner pad range, and an exact confirmed current unit price for this specific version could not be verified against a primary listing in this review, leaving format and category as the more reliable anchors. Medicube's parent, APR Corp, listed directly on the KOSPI main board on February 27, 2024, the first sub-ten-year-old startup to do so, and reported nine-month 2025 revenue of $666 million, up 100% year over year, with US sales up 250% year over year and now more than 32% of total revenue. Olive Young ran promotions on Medicube's device-led AGE-R line discounting up to 57% in January 2026, a scale of markdown that signals how aggressively the retailer is pushing the brand's broader catalogue, pads included. Newer independent entrants illustrate how contested that same shelf space has become: bttr's bttr [수분잠금] 하이드라 베리어 클렌징 336 밀크 투 폼 150g lists at ₩28,100 on the brand's own site, bttr.co.kr, as checked in 2026, but an Olive Young listing for bttr has not been confirmed through the retailer's own channels, unlike the six lines profiled in this comparison.

ZEROID Ato Concentrate Cream

The exact SKU queried under the name ZEROID Ato Concentrate Cream does not appear in Neopharm's current ZEROID catalogue; the brand's confirmed flagship is the ZEROID Intensive Cream, an 80ml jar that has carried bundle pricing between ₩28,800 and ₩32,000 on retailer listings checked in 2025. Neopharm builds the line around a proprietary Multi-Lamellar Emulsion barrier technology and also owns the sibling brands Atopalm, Real Barrier and Derma:B, all pitched at barrier repair rather than a single condition claim. ZEROID has an active official Olive Young brand store and appeared in the retailer's 2025 Awards listing, though the exact category placement was not confirmed in the pages reviewed. A comparable naming gap applies to Easydew DW-EGF Ampoule: Easydew, made by D&Cosmetics, a Daewoong Pharmaceutical affiliate, sells the DW-EGF platform across several distinct ampoules, including the DW-EGF Melatoning Oneday Ampoule and the DW-EGF Vitamin C Boosting Ampoule 25, rather than one product literally named 'DW-EGF Ampoule.' The platform is built around DW-EGF, sh-Oligopeptide-1, an engineered growth-factor peptide aimed at pigmentation and melasma brightening, priced across its SKUs from roughly ₩12,900 to ₩90,000 depending on size and format, and Daewoong's own press coverage credits the Melatoning Oneday Ampoule with more than 2 million units sold and over ₩100 billion in brand revenue, on an active Olive Young storefront.

Sources: L'Oreal Groupe press release on the Dr.G/Gowoonsesang acquisition, AESTURA's Olive Young Awards announcement, Olive Young 2025 Awards event page, Bloomberg reporting on Medicube/APR Corp's US retail push, and Torriden's official product listing at torriden.com for the DIVE-IN serum price.